• Listed Companies
  • Announcements
  • Tianjin Development Holdings Limited
  • EN
  • 繁
  • 简
  • 2021 Apr 28
    12:04

    Inside Information / Results of a Subsidiary

    Unaudited Financial Results for the three months ended 31 March 2021 of Tianjin Lisheng Pharmaceutical Co., Ltd.

    00882 - TIANJIN DEV


  • 2021 Apr 28
    06:43

    Notice of AGM

    Notice of Annual General Meeting

    00882 - TIANJIN DEV


  • 2021 Apr 28
    06:42

    Proxy Forms

    Form of Proxy for Annual General Meeting to be held on 24 June 2021

    00882 - TIANJIN DEV


  • 2021 Mar 30
    12:20

    Final Results / Dividend or Distribution / Closure of Books or Change of Book Closure Period

    Announcement of Final Results for the year ended 31 December 2020

    00882 - TIANJIN DEV


  • 2021 Mar 24
    12:07

    Inside Information / Results of a Subsidiary

    Audited Financial Results for the year ended 31 December 2020 of Tianjin Lisheng Pharmaceutical Co., Ltd.

    00882 - TIANJIN DEV


  • 2021 Mar 15
    18:26

    Date of Board Meeting

    Date of Board Meeting

    00882 - TIANJIN DEV


  • 2021 Mar 10
    20:37

    Profit Warning / Inside Information

    Profit Warning

    00882 - TIANJIN DEV


  • 2021 Feb 26
    16:31

    Inside Information / Overseas Regulatory Announcement - Trading Update

    Overseas Regulatory Announcement

    00882 - TIANJIN DEV


  • 2021 Jan 19
    19:03

    Continuing Connected Transaction

    Continuing Connected Transactions - Entrusted Processing Master Agreement

    00882 - TIANJIN DEV


  • 2020 Dec 30
    20:54

    Inside Information / Overseas Regulatory Announcement - Trading Update

    Overseas Regulatory Announcement

    00882 - TIANJIN DEV


  • «
  • ‹
  • 13
  • 14
  • 15
  • 16
  • 17
  • ›
  • »

Address

1/F, China Building,
29 Queen's Road Central, Hong Kong
(852) 3693 2688
info@cre8corp.com

Sitemap

  • Listed Companies
  • Disclaimer
  • Privacy Policy

Newsletter

Fill your email and sign up for monthly newsletter to keep updated

© Cre8ir 2023 All right reserved.